Clinical Trials Directory

Trials / Completed

CompletedNCT01591070

Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis

Phase 4 Study of Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
104 (actual)
Sponsor
Pusan National University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether proactive use of 0.1% tacrolimus ointment once or twice weekly can keep adult facial SD in remission and reduce the incidence of exacerbation.

Detailed description

Seborrhoeic dermatitis (SD) is a common chronic papulosquamous dermatosis, affecting 2% to 10% of the adult population, mainly those between the ages of 20 and 50 years with a male bias. The affected skin appears erythematous and oedematous, covered with yellow-brown scales, and is often accompanied by pruritus. It typically affects areas containing sebaceous glands, particularly the scalp, ears, face, chest, and intertriginous areas. SD has a chronic course, and relapse is common. Therefore, therapy is directed toward reducing the symptoms or aggravating factors of SD, such as loosening and removal of scales and crusts, inhibition of yeast colonization, control of secondary infection, and reduction of erythema and pruritus. Standard topical treatments for SD include corticosteroids and anti-mycotic medications. However, the chronic use of topical corticosteroids particularly on the face could result in undesirable outcomes, such as telangiectasia, atrophy, striae, peri-oral dermatitis, or tachyphylaxis, and early relapse after discontinuation of treatment. SD relapse prevention strategies have not yet been established, so the investigators suspected that intermittent use of tacrolimus ointment can be effective in preventing SD relapse.

Conditions

Interventions

TypeNameDescription
DRUGTacrolimus0.1% tacrolimus once-weekly application for 10 weeks
DRUGTacrolimus0.1% tacrolimus twice weekly application for 10 weeks

Timeline

Start date
2010-11-01
Primary completion
2011-05-01
Completion
2011-05-01
First posted
2012-05-03
Last updated
2012-08-08

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01591070. Inclusion in this directory is not an endorsement.